AstraZeneca is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma , The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist’s partners, which include Novartis , OncXerna and Ultragenyx .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
